Vanguard Group Inc Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$144.95 - $152.29 $1.03 Million - $1.08 Million	7,113 Added 0.5%	1,439,571 $218 Million
Q2 2022 Aug 12, 2022	BUY	$83.14 - $145.99 $892,258 - $1.57 Million	10,732 Added 0.75%	1,432,458 $209 Million
Q1 2022 May 13, 2022	BUY	$110.08 - $142.92 $5.79 Million - $7.52 Million	52,635 Added 3.84%	1,421,726 $169 Million
Q4 2021 Feb 14, 2022	SELL	$99.73 - $148.48 $886,599 - $1.32 Million	-8,890 Reduced 0.65%	1,369,091 $189 Million
Q3 2021 Nov 12, 2021	BUY	$98.85 - $138.91 $5.61 Million - $7.88 Million	56,711 Added 4.29%	1,377,981 $191 Million
Q2 2021 Aug 13, 2021	BUY	$65.78 - $105.02 $86.9 Million - $139 Million	1,321,270 New	1,321,270 $128 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.